🇺🇸 FDA
Patent

US 10857184

Materials and methods for engineering cells and uses thereof in immuno-oncology

granted A61KA61K2239/31A61K2239/38

Quick answer

US patent 10857184 (Materials and methods for engineering cells and uses thereof in immuno-oncology) held by CRISPR THERAPEUTICS AG expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K2239/31, A61K2239/38, A61K2239/48, A61K2239/56